Cobolimab |
WBP 296A; TSR-022; GSK-4069889 |
Phase 3 Clinical |
Anaptysbio Inc |
Liver Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
Sabatolimab |
MBG-453 |
Phase 3 Clinical |
Novartis Pharma Ag |
Preleukemia; Hematologic Diseases; Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Neoplasms; Glioblastoma; Primary Myelofibrosis; Bone Marrow Diseases; Leukemia, Myeloid, Acute |
Details
|
Surzebiclimab |
BGB-A425 |
Phase 2 Clinical |
Beigene Ltd |
Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck |
Details
|
Lomvastomig |
RG-7769; RO-7121661 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Neoplasms; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
BMS-986258 |
ONO-7807; BMS-986258 |
Phase 2 Clinical |
Five Prime Therapeutics Inc, Bristol-Myers Squibb Company |
Neoplasms |
Details
|
Sabestomig |
AZD-7789 |
Phase 2 Clinical |
AstraZeneca Ag |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Hodgkin Disease; Digestive System Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms |
Details
|
S-095018 |
S095018; S-095018 |
Phase 2 Clinical |
Servier Bio-Innovation LLC, Institut De Recherches Internationales Servier |
Carcinoma, Non-Small-Cell Lung |
Details
|
Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) |
|
Phase 2 Clinical |
Xuzhou Medical University (Xzmu), The Affiliated Hospital Of Xuzhou Medical University |
Leukemia, Myeloid, Acute |
Details
|
TB-006 |
TB-006; TB006 |
Phase 2 Clinical |
TrueBinding Inc |
Coronavirus Disease 2019 (COVID-19); Stroke; Alzheimer Disease |
Details
|
Verzistobart |
INCAGN-02390; INCAGN-2390 |
Phase 2 Clinical |
Incyte Corp, Agenus Inc |
Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Follicular; Uveal melanoma; Mesothelioma; Microsatellite instability-high cancer; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Ovarian Neoplasms; Carcinoma, Transitional Cell; Mismatch Repair Deficient Cancer; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Stomach Neoplasms; Esophageal Neoplasms; Lymphoma, B-Cell; Head and Neck Neoplasms |
Details
|
BC-3402 |
BC-3402 |
Phase 2 Clinical |
|
Solid tumours; Hematologic Diseases; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Carcinoma, Hepatocellular |
Details
|
TQB-2618(Jiangsu Chia Tai-Tianqing Pharmaceutical) |
TQB-2618 |
Phase 2 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Melanoma; Carcinoma, Hepatocellular |
Details
|
SHR-1702 |
SHR-1702 |
Phase 1 Clinical |
Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd |
Solid tumours; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
LY-3321367 |
LY-3321367 |
Phase 1 Clinical |
Eli Lilly And Company |
Solid tumours |
Details
|
KL-A293 |
KL-A293 |
Phase 1 Clinical |
Anyuan Pharmaceutical Technology (Shanghai) Co Ltd, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd |
Neoplasms |
Details
|
NB-002 (Suzhou Luosheng Bio-Pharmaceutical) |
NB-002 (Suzhou Luosheng Bio-Pharmaceutical); NB-002 (逻晟生物); NB-002 |
Phase 1 Clinical |
|
Solid tumours; Neoplasms |
Details
|
LPX-TI641 |
LPX-TI-641 |
Phase 1 Clinical |
LAPIX Therapeutics Inc |
Autoimmune Diseases; Multiple Sclerosis; Neuromyelitis Optica; Demyelinating Diseases |
Details
|
LB-1410 |
LB-1410 |
Phase 1 Clinical |
L&L Biopharma Co Ltd |
Solid tumours; Neoplasms; Lymphoma |
Details
|
Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) |
Bis-5 |
Phase 1 Clinical |
L&L Biopharma Co Ltd |
Solid tumours; Neoplasms |
Details
|
LBL-003 |
LBL-003 |
Phase 1 Clinical |
Nanjing Leads Biolabs Co Ltd |
Solid tumours; Neoplasms |
Details
|
Sym-023 |
Sym-023; Sym023; S95018 |
Phase 1 Clinical |
Symphogen A/S |
Solid tumours; Lymphoma; Neoplasm Metastasis |
Details
|
WBP-3425 |
WBP-3425 |
Phase 1 Clinical |
|
Solid tumours; Colonic Neoplasms |
Details
|
Cobolimab |
WBP 296A; TSR-022; GSK-4069889 |
Phase 3 Clinical |
Anaptysbio Inc |
Liver Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
Sabatolimab |
MBG-453 |
Phase 3 Clinical |
Novartis Pharma Ag |
Preleukemia; Hematologic Diseases; Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Neoplasms; Glioblastoma; Primary Myelofibrosis; Bone Marrow Diseases; Leukemia, Myeloid, Acute |
Details
|
Surzebiclimab |
BGB-A425 |
Phase 2 Clinical |
Beigene Ltd |
Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck |
Details
|
Lomvastomig |
RG-7769; RO-7121661 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Neoplasms; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
BMS-986258 |
ONO-7807; BMS-986258 |
Phase 2 Clinical |
Five Prime Therapeutics Inc, Bristol-Myers Squibb Company |
Neoplasms |
Details
|
Sabestomig |
AZD-7789 |
Phase 2 Clinical |
AstraZeneca Ag |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Hodgkin Disease; Digestive System Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms |
Details
|
S-095018 |
S095018; S-095018 |
Phase 2 Clinical |
Servier Bio-Innovation LLC, Institut De Recherches Internationales Servier |
Carcinoma, Non-Small-Cell Lung |
Details
|
Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) |
|
Phase 2 Clinical |
Xuzhou Medical University (Xzmu), The Affiliated Hospital Of Xuzhou Medical University |
Leukemia, Myeloid, Acute |
Details
|
TB-006 |
TB-006; TB006 |
Phase 2 Clinical |
TrueBinding Inc |
Coronavirus Disease 2019 (COVID-19); Stroke; Alzheimer Disease |
Details
|
Verzistobart |
INCAGN-02390; INCAGN-2390 |
Phase 2 Clinical |
Incyte Corp, Agenus Inc |
Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Follicular; Uveal melanoma; Mesothelioma; Microsatellite instability-high cancer; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Ovarian Neoplasms; Carcinoma, Transitional Cell; Mismatch Repair Deficient Cancer; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Stomach Neoplasms; Esophageal Neoplasms; Lymphoma, B-Cell; Head and Neck Neoplasms |
Details
|
BC-3402 |
BC-3402 |
Phase 2 Clinical |
|
Solid tumours; Hematologic Diseases; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Carcinoma, Hepatocellular |
Details
|
TQB-2618(Jiangsu Chia Tai-Tianqing Pharmaceutical) |
TQB-2618 |
Phase 2 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Melanoma; Carcinoma, Hepatocellular |
Details
|
SHR-1702 |
SHR-1702 |
Phase 1 Clinical |
Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd |
Solid tumours; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
LY-3321367 |
LY-3321367 |
Phase 1 Clinical |
Eli Lilly And Company |
Solid tumours |
Details
|
KL-A293 |
KL-A293 |
Phase 1 Clinical |
Anyuan Pharmaceutical Technology (Shanghai) Co Ltd, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd |
Neoplasms |
Details
|
NB-002 (Suzhou Luosheng Bio-Pharmaceutical) |
NB-002 (Suzhou Luosheng Bio-Pharmaceutical); NB-002 (逻晟生物); NB-002 |
Phase 1 Clinical |
|
Solid tumours; Neoplasms |
Details
|
LPX-TI641 |
LPX-TI-641 |
Phase 1 Clinical |
LAPIX Therapeutics Inc |
Autoimmune Diseases; Multiple Sclerosis; Neuromyelitis Optica; Demyelinating Diseases |
Details
|
LB-1410 |
LB-1410 |
Phase 1 Clinical |
L&L Biopharma Co Ltd |
Solid tumours; Neoplasms; Lymphoma |
Details
|
Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) |
Bis-5 |
Phase 1 Clinical |
L&L Biopharma Co Ltd |
Solid tumours; Neoplasms |
Details
|
LBL-003 |
LBL-003 |
Phase 1 Clinical |
Nanjing Leads Biolabs Co Ltd |
Solid tumours; Neoplasms |
Details
|
Sym-023 |
Sym-023; Sym023; S95018 |
Phase 1 Clinical |
Symphogen A/S |
Solid tumours; Lymphoma; Neoplasm Metastasis |
Details
|
WBP-3425 |
WBP-3425 |
Phase 1 Clinical |
|
Solid tumours; Colonic Neoplasms |
Details
|